[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Alume Biosciences, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100566970",false,"NCT06662097","A Study of Bevonescein in Patients Undergoing Abdominopelvic Surgery","Multicenter Open-Label Feasibility Study of Intraoperative Nerve and Ureter Visualization With Bevonescein in Patients Undergoing Minimally Invasive Abdominopelvic Surgery","Inclusion Criteria:\n\n* Must be a minimum of 18 years of age\n* Study participant is planning to proceed with surgery\n* Willing to provide informed consent\n* Sexually active patients must be willing to use an acceptable form of contraceptive while participating and 30 days after.\n* Females of childbearing potential must have a negative pregnancy test at screening and during the study.\n\nExclusion Criteria:\n\n* Patient has had prior surgery at the intended surgical site.\n* Patient has abnormal cardiac rhythm not controlled by medication.\n* Patient has moderate to severe renal impairment.\n* Patient has a history of fluorescein allergy.\n* Patient has a history of drug-related anaphylactic.\n* Presence of a concurrent disease or condition that may interfere with study participation.\n* Presence or history of any condition that, in the view of the investigator, places the patient at high risk of treatment compliance.\n* Use of any Investigational Product or investigational medial device within 30 days prior to screening.",true,"ALL","18 Years",{"count":19,"type":20},64,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Feasibility study of Bevonescein to highlight Nerves and Ureter in patients undergoing Minimally Invasive Surgery",[26,27,28],"Surgery","Nerve Injury","Imaging","RECRUITING","2024-10-25",{"date":32,"type":33},"2024-10-28","ACTUAL",{"date":35,"type":33},"2024-10-16",{"date":37,"type":20},"2025-09",{"name":39,"class":40},"Alume Biosciences, Inc.","INDUSTRY",""]